187 related articles for article (PubMed ID: 32247279)
41. T-cell prolymphocytic leukemia/lymphoma with TCRB::TCL1 translocation.
Torabi A; Naresh KN
Blood; 2023 Jul; 142(1):119. PubMed ID: 37410504
[No Abstract] [Full Text] [Related]
42. [T-cell prolymphocytic leukemia: potential diagnostic pitfalls].
Dessart P; Lemaire P; Le Dû K; Sandrini J; Prophette B; Maillard H
Ann Dermatol Venereol; 2014 Dec; 141(12):777-81. PubMed ID: 25433931
[TBL] [Abstract][Full Text] [Related]
43. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB; Herling M; Bellido M; Jacobsen ED; Davids MS; Kadia TM; Shustov A; Tournilhac O; Bachy E; Zaja F; Porkka K; Hoermann G; Simonitsch-Klupp I; Haferlach C; Kubicek S; Mayerhoefer ME; Hopfinger G; Jaeger U; Dearden C
Blood; 2019 Oct; 134(14):1132-1143. PubMed ID: 31292114
[TBL] [Abstract][Full Text] [Related]
44. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
Gualco G; Weiss LM; Barber GN; Bacchi CE
Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
[TBL] [Abstract][Full Text] [Related]
45. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas.
Gaudio E; Paduano F; Ngankeu A; Lovat F; Fabbri M; Sun HL; Gasparini P; Efanov A; Peng Y; Zanesi N; Shuaib MA; Rassenti LZ; Kipps TJ; Li C; Aqeilan RI; Lesinski GB; Trapasso F; Croce CM
Blood; 2013 Jan; 121(2):351-9. PubMed ID: 23160471
[TBL] [Abstract][Full Text] [Related]
46. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia.
Gritti C; Dastot H; Soulier J; Janin A; Daniel MT; Madani A; Grimber G; Briand P; Sigaux F; Stern MH
Blood; 1998 Jul; 92(2):368-73. PubMed ID: 9657733
[TBL] [Abstract][Full Text] [Related]
47. TCL1 expression predicts overall survival in patients with mantle cell lymphoma.
Shin SJ; Roh J; Cha HJ; Choi YD; Kim JM; Min SK; Kim JE; Eom DW; Lee H; Kim HJ; Yoon DH; Suh C; Huh J
Eur J Haematol; 2015 Dec; 95(6):583-94. PubMed ID: 25688912
[TBL] [Abstract][Full Text] [Related]
48. [Transgenic mice expressing MTCP1: an animal model for T-cell prolymphocytic leukemia].
Chiali-Gritti C
Ann Pharm Fr; 2000 Jan; 58(1):54-61. PubMed ID: 10669814
[TBL] [Abstract][Full Text] [Related]
49. T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches.
Colon Ramos A; Tarekegn K; Aujla A; Garcia de de Jesus K; Gupta S
Cureus; 2021 Feb; 13(2):e13237. PubMed ID: 33728186
[TBL] [Abstract][Full Text] [Related]
50. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
[TBL] [Abstract][Full Text] [Related]
51. TCL1 is activated by chromosomal rearrangement or by hypomethylation.
Yuille MR; Condie A; Stone EM; Wilsher J; Bradshaw PS; Brooks L; Catovsky D
Genes Chromosomes Cancer; 2001 Apr; 30(4):336-41. PubMed ID: 11241786
[TBL] [Abstract][Full Text] [Related]
52. Recurrence of T-Cell Prolymphocytic Leukemia With a Rare Presentation as Diffuse Generalized Skin Lesion.
Wasifuddin M; Sabzposh H; Sun L; Wu R; Wang JC
J Investig Med High Impact Case Rep; 2023; 11():23247096231176223. PubMed ID: 37219076
[TBL] [Abstract][Full Text] [Related]
53. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
[TBL] [Abstract][Full Text] [Related]
54. [Research Advances of Genetics, Diagnosis and Treatment of T-cell Prolymphocytic Leukemia--Review].
Lai MF; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1977-1981. PubMed ID: 34893145
[TBL] [Abstract][Full Text] [Related]
55. Expression of S100 Protein in CD4-positive T-cell Lymphomas Is Often Associated With T-cell Prolymphocytic Leukemia.
Aggarwal N; Pongpruttipan T; Patel S; Bayerl MG; Alkan S; Nathwani B; Surti U; Kitahara S; Chinthammitr Y; Swerdlow SH
Am J Surg Pathol; 2015 Dec; 39(12):1679-87. PubMed ID: 26379148
[TBL] [Abstract][Full Text] [Related]
56. Cutaneous involvement by T-cell prolymphocytic leukemia presenting as livedoid vasculopathy.
Leckey BD; Kheterpal MK; Selim MA; Al-Rohil RN
J Cutan Pathol; 2021 Jul; 48(7):975-979. PubMed ID: 33837964
[TBL] [Abstract][Full Text] [Related]
57. The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways.
Despouy G; Joiner M; Le Toriellec E; Weil R; Stern MH
Blood; 2007 Dec; 110(13):4406-16. PubMed ID: 17846228
[TBL] [Abstract][Full Text] [Related]
58. Deregulated expression of TCL1 causes T cell leukemia in mice.
Virgilio L; Lazzeri C; Bichi R; Nibu K; Narducci MG; Russo G; Rothstein JL; Croce CM
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3885-9. PubMed ID: 9520462
[TBL] [Abstract][Full Text] [Related]
59. Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.
Mikhaylenko N; Wahnschaffe L; Herling M; Roeder I; Seifert M
PLoS One; 2022; 17(9):e0274463. PubMed ID: 36129940
[TBL] [Abstract][Full Text] [Related]
60. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement.
Hsi AC; Robirds DH; Luo J; Kreisel FH; Frater JL; Nguyen TT
Am J Surg Pathol; 2014 Nov; 38(11):1468-83. PubMed ID: 25310835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
